SCHEMBL20425545

SCHEMBL20425545

O=C(O)Nc1cc2cnc(Cl)nc2n1C1CCCC1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 18/20 0.45
CCND1 P24385 13/20 0.45
CDK2 P24941 5/20 0.39
CCNA2 P20248 2/20 0.39
CCND3 P30281 10/20 0.39
CCNE1 P24864 3/20 0.39
CDK6 Q00534 3/20 0.39
CCNT1 O60563 3/20 0.39
CDK9 P50750 3/20 0.39
CCND2 P30279 3/20 0.37
FGFR1 P11362 1/20 0.37
FGFR2 P21802 1/20 0.37
FGFR4 P22455 1/20 0.37
FGFR3 P22607 1/20 0.37
AURKA O14965 1/20 0.37
CDK1 P06493 1/20 0.37
AURKB Q96GD4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30577928 0.83 OPRM1 (0.41) CDK4CCND1CDK2CCND3CCNE1
SCHEMBL1991171 0.81 CDK4 (0.50) CDK4CCND1CDK2CCNA2CCND3
SCHEMBL22174830 0.78 CDK4 (0.49) CDK4CCND1CDK2CCNA2CCND3
SCHEMBL4189989 0.77 CCNT1 (0.42) CDK4CCND1CDK2CCNA2CCND3
SCHEMBL19711678 0.77 CDK4 (0.51) CDK4CCND1CDK2CCNA2CCND3
SCHEMBL1988950 0.77 CDK4 (0.52) CDK4CCND1CDK2CCND3CCNE1
SCHEMBL20425411 0.77 CDK4 (0.53) CDK4CCND1CDK2CCND3CCNE1
SCHEMBL31372001 0.77 CDK4 (0.53) CDK4CCND1CDK2CCND3CCNE1
SCHEMBL31475403 0.75 CDK2 (0.57) CDK4CCND1CDK2CCNA2CCND3
SCHEMBL22174831 0.75 CDK4 (0.50) CDK4CCND1CDK2CCND3CCNE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240043445-A1 Thienopyranones and Furanopyranones as Kinase, Bromodomain, and Checkpoint Inhibitors SIGNALRX PHARMACEUTICALS, INC. (US) 2024-02-08 US disclosed
US-11760762-B2 Thienopyranones and furanopyranones as kinase, bromodomain, and checkpoint inhibitors SIGNALRX PHARMACEUTICALS, INC. (US) 2023-09-19 US disclosed
EP-3573619-A1 THIENOPYRANONES AND FURANOPYRANONES AS KINASE, BROMODOMAIN, AND CHECKPOINT INHIBITORS SignalRX Pharmaceuticals, Inc. (US) 2019-12-04 EP disclosed
WO-2018140730-A1 THIENOPYRANONES AND FURANOPYRANONES AS KINASE, BROMODOMAIN, AND CHECKPOINT INHIBITORS SIGNALRX PHARMACEUTICALS, INC. (US) 2018-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11760762-B2 Thienopyranones and furanopyranones as kinase, bromodomain, and checkpoint inhibitors CDK1, CDKN1A, CDKL1 CDK4 8/4885CCND1 11/4885CDK2 4/4885
US-20240043445-A1 Thienopyranones and Furanopyranones as Kinase, Bromodomain, and Checkpoint Inhibitors CDK1, CDKN1A, CDKL1 CDK4 8/4885CCND1 11/4885CDK2 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.